The Insight Partners Latest Research on Report “Anticoagulant Reversal Drugs Market Forecast to 2027 – COVID-19 Impact and Global Analysis By Product (Prothrombin Complex Concentrates, Vitamin K, Protamine, Tranexamic Acid, Idarucizumab, and AndeXXa), and Distribution channel (Hospital Pharmacies, Retail Pharmacies, and Others) and Geography
“Anticoagulant Reversal Drugs Market is expected to reach US$ 2,276.54 million by 2027 from US$ 922.55 in 2019; it is estimated to grow at a CAGR of 12.6%from 2020 to 2027. The report highlights trends prevailing in the global anticoagulant reversal drugs market, and drivers and hindrances pertaining to the market growth.
Download PDF Sample Copy at:
https://www.theinsightpartners.com/sample/TIPRE00004954/
Anticoagulant reversal drugs are required to reverse the effect of anticoagulation in certain situations such as unplanned surgery, overdose of anticoagulant therapy, and uncontrolled bleeding. In medical conditions such as venous thromboembolism, atrial fibrillation (AF), mechanical valve replacement, and other coagulation disorders such as antiphospholipid antibody syndrome, Factor V Leiden, anticoagulant reversal drugs are used.
Market Players:
Market leaders operating in the market have undertaken various organic growth strategies in the anticoagulant reversal drugs market. The anticoagulant reversal drugs majorly consist of the players such as Boehringer Ingelheim International GmbH; Pfizer Inc; Octapharma AG; Amag Pharmaceuticals, Inc; Fresenius Kabi AG; Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals); CSL Limited; China Biologic Products, Inc; Grifols, S.A, and Shanghai RAAS Blood Products Co., Ltd. among others. Companies such as Boehringer Ingelheim International GmbH, Pfizer Inc, AMAG PHARMACEUTICALS, INC., Portola Pharmaceuticals, China Biologic Products, Inc, Grifols, S.A., Shanghai RAAS Blood Products Co., Ltd. have been implementing various inorganic developments that have bought about dynamic improvements in the market
Below is the list of the growth strategies done by the players operating in the anticoagulant reversal drugs market:
Nov- 2020: B. Braun Melsungen AG and Grifols form strategic alliance to offer integrated solutions for safe automated drug preparation and administration
April-2020: Portola Pharmaceuticals Inc. agreed to terminate its collaboration and license agreement with Bristol-Myers Squibb Co. and Pfizer Inc. for the development and commercialization of andexanet alfa in Japan
July-2020: Alexion Completes Acquisition of Portola. The acquisition adds Factor Xa inhibitor reversal agent Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo], marketed as Ondexxya in Europe, to Alexion’s commercial portfolio
Inquire about Discount:
https://www.theinsightpartners.com/inquiry/TIPRE00004954/
Geographical Analysis:
Geographically, the anticoagulant reversal drugs market is segmented into North America, Europe, Asia Pacific, the Middle East and Africa, and South and Central America. North America held the largest market share in 2019. In North America, the US is the largest market for anticoagulant reversal drugs. The growth of the market in the region is attributed to the presence of key market players and their product development efforts. Additionally, the escalating prevalence of atrial fibrillation further contributes to the growth of the anticoagulant reversal drugs market in North America.
Segments:
Based on distribution channel, the anticoagulant reversal drugs market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the largest share of the market in 2019, and is estimated to register the highest CAGR in the market during the forecast period. Hospital pharmacies offer complex and specialized medicines, which may not be available in a retail pharmacy. It ensures the availability of right medication, in the right dose and at the right time. These factors are expected to contribute to the growth of the market during the forecast period.
Based on product, the anticoagulant reversal drugs market is segmented into prothrombin complex concentrates, vitamin k, protamine, tranexamic acid, idarucizumab, and AndeXXa. The prothrombin complex concentrates segment held the largest share of the market in 2019; whereas, the AndeXXa segment is estimated to register the highest CAGR in the market during the forecast period. Prothrombin complex concentrates are widely used as a reliable and fast alternative to fresh frozen plasma and controls excessive bleeding.
Buy Report at:
https://www.theinsightpartners.com/buy/TIPRE00004954/
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876